Session I: Challenges in research methodology
Moderators:
Dr. Jamal Eddin Zekri
Dr. Ahmed Alrefaee
19:00 –19:20
Surrogate vs. definitive endpoints
Dr. Soha Elmorsy
19:20-19:40
Interim analysis: pros/cons
Dr. Khalid AlSaleh
19:40-20:00
Artificial intelligence: impact on oncology research and practice
Dr. Soha Elmorsy
20:00-20:20
Local research challenges in Saudi Arabia
Dr. Atlal Abusanad
20:40-21:20
Session II: Lung Cancer Stage III NSCLC; best therapeutic approaches
Panel: Ahmed Alfaraj, Turki Alfayea, Ahmed Alwbari, Abdullah Altwairgi, Omima Elemam, Nafisa Abdelhafiez
Moderator: Waleed Bahaj
Dr. Ahmed Alfaraj
Dr. Turki Alfayea
Dr. Ahmed Alwabari
Dr. Abdullah Altwergi
Dr. Omaima Elemam
Dr. Nafisa Abdelhafeez
Dr. Waleed Bahaj
21:20-22:00
Satellite symposium
09:00-9:30
Session I: GU cancers Doublet vs. triplet therapy in hormonal sensitive metastatic prostate cancer
Panel: Hani Elkhatib, Abdullah Alsharm, Faisal Albadainah, Jawaher Ansari, Rula Almufti , Emad Tashkandi, Fahad Almugbel
Moderator: Mubarak Almansour
Dr. Hani Elkhatib
Dr. Abdullah Alsharm
Faisal Albadainah
Dr. Jawaher Ansari
Dr. Rula Almufti
Dr. Emad Tashkandi
Dr. Fahad Almugbel
Dr. Mubarak Almansour
09:30-10:10
Session II: GU cancers PARPi in mCRCP : single agent or in combination with novel ADT
Panel: Hani Elkhatib, Mubarak Almansour, Faisal Albadainah, Jawaher Ansari, Roula Almufti , Emad Tashkandi, Fahad Almugbel
Moderator: Abdullah Alsharm
Dr. Hani Elkhatib
Dr. Mubarak Almansour
Faisal Albadainah
Dr. Jawaher Ansari
Dr. Rula Almufti
Dr. Emad Tashkandi
Dr. Fahad Almugbel
10:40-11:20
Session III: Breast cancer ADCs in advanced breast cancer: current challenges and future prospects
- Sequencing of ADCs/cross resistance?
- Impact of repeating biopsy?
- De-escalation in excellent responders? – Monitoring of toxicity
Panel: Esam Murshid, Ahmed Saadeddin, Ahmed Refae, Fadi Farhat, Shadi Alkhayyat, Shereef Elsamany, Atlal Abusanad
Moderator: Ahmed Alwbari
Dr. Essam Murshid
Dr. Ahmed Saadeldin
Dr. Ahmed Alrefaee
Dr. Fadi Farhat
Dr. Shadi Khayat
Dr. Shereef Elsamany
Dr. Atlal Abusanad
Session IV: Breast Cancer CDK4/6 inhibitors in advanced HR+/HER2- BC: 1st vs. 2nd line
14:00-14:15
CDK 4-6 inhibitors in 1st line for all patients
Prof. Guessepi Currigliano
14:15-14:30
CDK 4-6 inhibitors can be deferred to 2nd line
Dr. Hamdy Abdelazim
14:30-14:50
Panel Discussion: Guessepi Currigliano, Ahmed Saadelddin, Adher Alsayed, Bassam Basulaiman, Aboelkhair Algahmi, Marwan Ghosn
Moderator: Hamdy Abdelazim
Prof. Guessepi Currigliano
Dr. Ahmed Saadeldin
Dr. Adher Alsayed
Dr. Bassam Basuliman
Dr. Aboelkhair Algahami
Dr. Marwan Ghosn
Dr. Hamdy Abdelazim
14:50-15:30
Session V: Breast Cancer Adjuvant CDK 4-6 inhibitors: challenging clinical scenarios
- Role of molecular tools in patient selection
- Timing of initiation of adjuvant CDK 4-6 inhibitors
- Can we switch from abemaciclib to ribociclib/vice versa, what about duration of CDK4-6 inhibitor treatment?
- Duration of adjuvant hormonal therapy
Panel: Omelkhair Abulkhair, Guessepi Currigliano , Adher Elsayed, Meteb Alfoheidi, Ahmed Zeeneldin, Ahmed Alshehri
Moderator: Shereef Elsamany
Dr. Omelkhair Abulkhair
Prof. Guessepi Currigliano
Dr. Adher Alsayed
Dr. Meteb Alfoheidi
Dr. Ahmed Zeeneldin
Dr. Ahmed Alshehri
Dr. Shereef Elsamany
Contact Us